[SCHEDULE 13G] BioLineRX Ltd SEC Filing

Rhea-AI Filing Summary

Highbridge Capital Management disclosed a 7.2% position in BioLineRx Ltd. represented by 172,950,600 Ordinary Shares assuming exercise of warrants held by Highbridge Funds. The filing states these shares are represented by 288,251 ADSs issuable upon exercise of warrants and that each ADS represents 600 Ordinary Shares. Highbridge reports sole voting and dispositive power over the 172,950,600 Ordinary Shares. The percentage is calculated using an outstanding share base of 2,232,601,990 Ordinary Shares as reported by the issuer.

Positive

• Material disclosure of a >5% position providing transparency to the market
• Sole voting and dispositive power clearly stated for the reported shares
• Quantified stake with explicit share counts and basis for percentage calculation

Negative

• Position is dependent on exercise of warrants/ADSs, so actual current ownership may differ from the reported 172,950,600 Ordinary Shares
• Potential dilution or increased supply could result if warrants are exercised, since the holding is reported on an as-exercised basis

Insights

Financial Analyst

TL;DR: A sizable, potentially dilutive stake: 7.2% of class, held via warrants/ADSs with sole voting and dispositive power.

The filing documents a material position by an institutional investor controlling 172,950,600 Ordinary Shares on an as-exercised basis, equal to 7.2% of the reported outstanding shares. The position is exercisable through warrants reflected as 288,251 ADSs, each ADS equal to 600 Ordinary Shares, indicating that the reported stake depends on warrant exercise. For investors, this means a notable concentration of potential supply and an active institutional holder with voting and disposal authority. The disclosure is standard for a fund reporting greater-than-5% economic exposure through derivatives converted to ADSs.

Corporate Governance Expert

TL;DR: Reporting shows sole control over reported shares and potential influence from an institutional holder exceeding 5%.

The statement clarifies that Highbridge has sole voting and dispositive power over the 172,950,600 Ordinary Shares reported, which can confer influence over corporate matters if the warrants are exercised and ADSs are converted. The filing also identifies a specific Highbridge fund that holds rights to dividends or sale proceeds for more than 5% of the class, which is a governance-relevant disclosure. The form includes required certifications that the securities are held in the ordinary course of business.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

BioLineRx Ltd.

(Name of Issuer)

Ordinary Shares, par value NIS 0.10 per share

(Title of Class of Securities)

09071M304

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 09071M304

1

Names of Reporting Persons

Highbridge Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 172,950,600.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 172,950,600.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

172,950,600.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.2 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: The 172,950,600 Ordinary Shares (as defined in Item 2(a)) reported herein are represented by 288,251 ADSs (as defined in Item 2(a)) issuable upon exercise of warrants.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: BioLineRx Ltd.
(b)	Address of issuer's principal executive offices: 2 HAMA-AYAN STREET, MODI-IN, Israel 7177871
Item 2.
(a)	Name of person filing: This statement is filed by Highbridge Capital Management, LLC ("Highbridge" or the "Reporting Person"), a Delaware limited liability company and the investment adviser to certain funds and accounts (the "Highbridge Funds"), with respect to the ordinary shares, par value NIS 0.10 per share ("Ordinary Shares"), of BioLineRx Ltd., an Israeli corporation (the "Issuer"), issuable upon exercise of warrants directly held, in the form of American Depositary Shares ("ADSs"), by the Highbridge Funds. There is no CUSIP number assigned to the Ordinary Shares. The CUSIP Number 09071M304 has been assigned to the ADSs of the Issuer, which are quoted on the Nasdaq Capital Market under the symbol "BLRX." Each ADS represents 600 Ordinary Shares. The filing of this statement should not be construed as an admission that any of the foregoing persons or the Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the securities reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of the Reporting Person is 277 Park Avenue, 23rd Floor, New York, New York 10172.
(c)	Citizenship: Highbridge is a Delaware limited liability company.
(d)	Title of class of securities: Ordinary Shares, par value NIS 0.10 per share
(e)	CUSIP No.: 09071M304
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for the Reporting Person and is incorporated herein by reference. The percentage set forth in this Schedule 13G is calculated based upon an aggregate of 2,232,601,990 Ordinary Shares outstanding as of May 15, 2025, as reported in Exhibit 99.1 to the Report of Foreign Private Issuer on Form 6-K filed with the Securities and Exchange Commission on May 23, 2025, and assumes the exercise of the warrants held by the Highbridge Funds.
(b)	Percent of class: 7.2%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for the Reporting Person and is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for the Reporting Person and is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for the Reporting Person and is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). The Highbridge Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares reported herein. Highbridge Tactical Credit Master Fund, L.P., a Highbridge Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Ordinary Shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Highbridge Capital Management, LLC

Signature:	/s/ Kirk Rule
Name/Title:	Kirk Rule, Executive Director
Date:	08/14/2025

FAQ

What stake in BioLineRx (BLRX) does Highbridge report?

Highbridge reports beneficial ownership of 172,950,600 Ordinary Shares, representing 7.2% of the class on an as-exercised basis.

Are the reported BioLineRx shares currently outstanding or based on warrants/ADSs?

The reported amount is based on warrants issuable in the form of 288,251 ADSs; each ADS represents 600 Ordinary Shares.

Does Highbridge have voting control over the reported BLRX shares?

Yes. The filing states Highbridge has sole voting power and sole dispositive power over the 172,950,600 Ordinary Shares reported.

How was the 7.2% figure calculated for BLRX?

The percentage uses an outstanding share base of 2,232,601,990 Ordinary Shares as reported by the issuer and assumes exercise of the warrants held by Highbridge Funds.

Which Highbridge fund holds more than 5% of BLRX on behalf of another person?

Highbridge Tactical Credit Master Fund, L.P. is identified as having the right to dividends or proceeds for more than 5% of the Ordinary Shares.